CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies worldwide. The long-term prognosis for HCC remains extremely poor, with drug resistance being the major underlying cause of recurrence and mortality. The lncRNA colorectal neoplasia differentially express...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu-Chin, Lin, Yang-Hsiang, Chi, Hsiang-Cheng, Huang, Po-Shuan, Liao, Chia-Jung, Liou, Yu-Syuan, Lin, Chiao-Chun, Yu, Chia-Jung, Yeh, Chau-Ting, Huang, Ya-Hui, Lin, Kwang-Huei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400329/
https://www.ncbi.nlm.nih.gov/pubmed/35999564
http://dx.doi.org/10.1186/s13148-022-01326-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400329/
https://www.ncbi.nlm.nih.gov/pubmed/35999564
http://dx.doi.org/10.1186/s13148-022-01326-3

Ejemplares similares